The IC50 values were calculated for all the treatments, with the order of potency in H1299 and H1975 following PPL [5.84 ± 0.04 μM] > CIS [57.63 ± 3.06 μM] > ERL [138.88 ± 9.62 μM] > GEF [219.43 ± 22.69 μM], and PPL [6.05 ± 0.31 μM] > GEF [47.22 ± 3.97 μM] > ERL [51.92 ± 2.34 μM] > CIS [100 ± 3.06 μM], respectively. The gene discussed is PPL; the disease is in situ carcinoma.